Oral BPC 157 rescued platelet aggregation function inhibited by three common blood-thinning drugs in rats, without affecting the broader coagulation system.
Platelet function rescuedBPC 157 reversed antiplatelet effects of 3 different drugs across 4 aggregation pathways without affecting the coagulation cascade
What the researchers found
BPC 157 (10 µg/kg, given orally) counteracted the inhibitory effects of aspirin, clopidogrel, and cilostazol on platelet aggregation across multiple activation pathways:
- Reversed arachidonic acid-induced aggregation inhibition (vs. all three drugs)
- Reversed arachidonic acid/PGE1 aggregation inhibition (vs. cilostazol)
- Reversed ADP-induced aggregation inhibition (vs. clopidogrel)
- Reversed collagen-induced aggregation inhibition (vs. clopidogrel)
Critically, BPC 157 had no effect on extrinsic/intrinsic hemostasis or fibrin clot parameters (EXTEM, INTEM, FIBTEM measurements were unchanged), demonstrating specificity for platelet function rescue.
Why it matters
Blood-thinning drugs are essential for preventing heart attacks and strokes but increase bleeding risk. A peptide that could selectively rescue platelet function when needed — for example before emergency surgery in patients on antiplatelet therapy — would address a significant clinical gap.
How the study worked
Wistar rats received daily oral dosing of antithrombotic agents (aspirin, clopidogrel, or cilostazol at 10 mg/kg) with either BPC 157 (10 µg/kg) or saline for three days. Blood was sampled 2 hours after the last dose. Multiple electrode aggregometry measured platelet aggregation with four different agonists, and rotational thromboelastometry assessed overall clot formation parameters.
What this study cannot tell us
Animal study in rats — human translation is unknown. The study comes from the primary BPC 157 research group, and independent replication is needed. The mechanism by which BPC 157 rescues platelet function is not explained. It's unclear whether this effect could dangerously counteract the therapeutic antiplatelet effects needed to prevent heart attacks. No human pharmacokinetic or safety data exists for BPC 157.
How to read the evidence
Preclinical animal study with rigorous platelet function testing using both aggregometry and thromboelastometry. However, all evidence is in rats with no human data, and the study is from the primary BPC 157 research group.
When this study was published
Published in 2019 in Oxidative Medicine and Cellular Longevity. BPC 157 still lacks human clinical trials for any indication as of 2026.
The bigger picture
This study adds to the growing BPC 157 literature showing protective effects across the cardiovascular system. The selective rescue of platelet function without affecting the broader coagulation cascade is a notable finding that, if validated in humans, could have practical clinical applications in managing bleeding risk from antiplatelet drugs.
Questions still open
- Through what molecular mechanism does BPC 157 restore platelet aggregation inhibited by three different drug classes?
- Could BPC 157's platelet rescue effect be dangerous for patients who need antiplatelet therapy to prevent thrombotic events?
- Would BPC 157 be useful as an emergency reversal agent for antiplatelet drugs before urgent surgery?
Common questions
Could BPC 157 interfere with blood-thinning medications?
Is this a good or bad thing for BPC 157?
Read the original research
Intragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot.
Oxidative medicine and cellular longevity, 2019, 9084643
Citation
Konosic, Sanja; Petricevic, Mate; Ivancan, Visnja; Konosic, Lucija; Goluza, Eleonora; Krtalic, Branimir; Drmic, Domagoj; Stupnisek, Mirjana; Seiwerth, Sven; Sikiric, Predrag. (2019). Intragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot.. Oxidative medicine and cellular longevity, 2019, 9084643. https://doi.org/10.1155/2019/9084643